BEETroot Juice to Reverse Functional Impairment in PAD
NCT05624125 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210
Last updated 2026-04-15
Summary
The BEET PAD Trial is a multi-centered double-blind randomized clinical trial designed to determine whether beetroot juice, compared to placebo, improves six-minute walk distance at four month follow-up in people with lower extremity peripheral artery disease (PAD). Investigators hypothesize that by simultaneously increasing lower extremity perfusion, gastrocnemius muscle mitochondrial activity, and myofiber health and regeneration, beetroot juice will significantly improve walking performance in people with PAD. The primary aim is to determine whether beetroot juice significantly improves six-minute walk distance at 4-month follow-up in people with PAD, compared to placebo. Preliminary evidence suggests that beetroot juice has both acute and chronic effects on walking performance in PAD. The primary outcome will measure the combined acute and chronic effect of beetroot juice (i.e. the maximal effect) on change in 6-minute walk at 4-month follow-up. In secondary aims, investigators will distinguish between acute and chronic effects of beetroot juice on six-minute walk and delineate biologic pathways by which beetroot juice improves walking performance in PAD, by measuring change in gastrocnemius muscle perfusion (MRI arterial spin labeling) and gastrocnemius muscle health. The trial will assess the durability of beetroot juice effects on six-minute walk. Nitrate in beetroot juice is metabolized to nitrite and subsequently to NO, attaining peak nitrite levels 2.5 hours after ingestion. The trial will determine whether a higher peak or a greater increase in plasma nitrite at 2.5 hours after beetroot juice consumption at baseline has a greater effect on six-minute walk at 4-month follow-up, compared to a lower peak or a smaller increase, respectively.
Conditions
Interventions
- OTHER
-
Beetroot juice
Two 70 ml beetroot juice drinks daily for 4 months.
- OTHER
-
Placebo
Two 70 ml placebo drinks daily for 4 months.
Sponsors & Collaborators
-
University of Virginia
collaborator OTHER -
University of Chicago
collaborator OTHER -
National Institute on Aging (NIA)
collaborator NIH - lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-25
- Primary Completion
- 2028-04-01
- Completion
- 2028-10-01
Countries
- United States
Study Locations
More Related Trials
-
Carnosine for Peripheral Arterial Disease
NCT04870229 ·Status: COMPLETED ·Phase: PHASE2
-
Hepatocyte Growth Factor to Improve Functioning in PAD
NCT03363165 ·Status: COMPLETED ·Phase: PHASE2
-
Carnosine for Peripheral Arterial Disease Patients
NCT05371145 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy
NCT02653833 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
NCT03743636 ·Status: COMPLETED ·Phase: PHASE3
-
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
NCT03506633 ·Status: COMPLETED ·Phase: NA
-
Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
NCT02636283 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
NCT06480760 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
NCT00029991 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
NCT06319339 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC
NCT03683628 ·Status: UNKNOWN ·Phase: NA
-
Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD
NCT04305028 ·Status: UNKNOWN
-
Fisetin to Reduce Senescence and Mobility Impairment in PAD
NCT06399809 ·Status: RECRUITING ·Phase: PHASE2
-
The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication
NCT01799057 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)
NCT00399919 ·Status: COMPLETED ·Phase: PHASE3
-
Carnosine for Peripheral Vascular Disease
NCT03844113 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
NCT01256775 ·Status: COMPLETED ·Phase: PHASE2
-
Patients' Perspectives of Factors That Support the Management of Peripheral Arterial Disease for Improved Outcomes
NCT01419418 ·Status: COMPLETED
-
Evaluation of MST-188 in Acute Lower Limb Ischemia
NCT02093468 ·Status: TERMINATED ·Phase: PHASE2
-
Trial of VLTS-589 in Subjects With Intermittent Claudication
NCT00068133 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Neo40 on PAD
NCT02934438 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
NCT00117650 ·Status: COMPLETED ·Phase: PHASE2
-
Cilostazol After Lower Extremity Arterial Revascularization Trial
NCT02374957 ·Status: TERMINATED ·Phase: PHASE4
-
Unacylated Ghrelin to Improve Functioning in PAD
NCT04377126 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
NCT01848210 ·Status: COMPLETED ·Phase: PHASE4